版本:
中国

BRIEF-Crispr Therapeutics Q4 earnings per share $0.40

March 10 Crispr Therapeutics AG:

* Crispr Therapeutics reports fourth quarter and full year 2016 financial results and provides business update

* Crispr Therapeutics -on track to file its clinical trial authorization in Europe by year-end 2017 for lead therapeutic product to treat beta-thalassemia

* Crispr Therapeutics - expects existing cash resources will enable co to fund operating expenses, capital expenditure requirements for at least next 2 years

* Qtrly earnings per share $0.40

* Qtrly collaborative revenue $2.3 million versus $247,000 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐